The pharmaceutical industry is in crisis. Big, profitable products are losing their patent protection and generic producers are jumping in to take a growing share of the market. We look at how the big pharmas, and the smaller ones, can find a way through these troubled times.
The Nineties saw a whole wave of market liberalisations. Arthur D. Little has helped former monopolies and market entrants alike in designing strategies for liberalised markets. Read about the views and conclusions from a new entrant's perspective.
When the reengineering wave of the 1990s hit R&D operations, Chief Technology Officers (CTOs) jumped to justify their companies' R&D spending levels, striving for functional efficiency, process effectiveness, and value for money invested.
With more than 100,000 employees and assets valued at $80 billion, the Royal Dutch/Shell Group is a global giant in the energy industry, involved in the whole production process of fossil fuels – – from initial prospecting and recovery to final sale – as well as other businesses, such as...
If you believe that your chief source of sustainable business success is the company's skill, knowledge, and information, you are likely in the forefront of the new economy – an economy fueled by intellectual assets, rather than hard assets.